Curanex Pharmaceuticals Inc SEC filings CURX
Curanex Pharmaceuticals Inc has 65 filings in SEC EDGAR's recent list, going back to Jun 20, 2024. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Oct 19, 2026 | — |
| 8-K |
Current report
Other events
|
Oct 19, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 4, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Aug 17, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| S-8 | Employee stock plan registration | Jul 21, 2026 | — |
| DEF 14C | Information statement | Jun 29, 2026 | Jun 29, 2026 |
| PRE 14C | Filing | Jun 18, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
May 7, 2026 | May 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 2, 2026 | Apr 2, 2026 |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Mar 6, 2026 | Mar 1, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 5, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 17, 2025 | Sep 30, 2025 |
| NT 10-Q | Filing | Nov 17, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Listing notice
|
Nov 6, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Sep 29, 2025 | Sep 23, 2025 |
| 8-K |
Current report
Other events
|
Sep 12, 2025 | Sep 12, 2025 |
| 10-Q | Quarterly report | Sep 9, 2025 | Jun 30, 2025 |
| 3 | Initial insider ownership | Sep 2, 2025 | Aug 25, 2025 |
| 3 | Initial insider ownership | Sep 2, 2025 | Aug 25, 2025 |
| 3 | Initial insider ownership | Sep 2, 2025 | Aug 25, 2025 |
| 3 | Initial insider ownership | Sep 2, 2025 | Aug 25, 2025 |
| 3 | Initial insider ownership | Sep 2, 2025 | Aug 25, 2025 |
| 3 | Initial insider ownership | Sep 2, 2025 | Aug 25, 2025 |
| 3 | Initial insider ownership | Sep 2, 2025 | Aug 25, 2025 |
| 3 | Initial insider ownership | Sep 2, 2025 | Aug 25, 2025 |
| 3 | Initial insider ownership | Sep 2, 2025 | Aug 25, 2025 |
| 8-K |
Current report
Other events
|
Aug 27, 2025 | Aug 27, 2025 |
| 424B4 | Prospectus | Aug 26, 2025 | — |
| 424B4 | Prospectus | Aug 26, 2025 | — |
| 8-K |
Current report
Material agreement, Other events
|
Aug 26, 2025 | Aug 25, 2025 |
| CERT | Filing | Aug 25, 2025 | — |
| 8-A12B | Filing | Aug 25, 2025 | — |
| EFFECT | Filing | Aug 12, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| FWP | Free writing prospectus | Jul 22, 2025 | — |
| S-1/A | Amended registration statement | Jul 18, 2025 | — |
| FWP | Free writing prospectus | Jul 10, 2025 | — |
| S-1/A | Amended registration statement | Jul 1, 2025 | — |
| CORRESP | Letter to the SEC | Apr 9, 2025 | — |
| CORRESP | Letter to the SEC | Apr 8, 2025 | — |
| CORRESP | Letter to the SEC | Apr 8, 2025 | — |
| FWP | Free writing prospectus | Mar 19, 2025 | — |
| CORRESP | Letter to the SEC | Mar 17, 2025 | — |
| S-1/A | Amended registration statement | Mar 17, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 21, 2025 | — |
| S-1/A | Amended registration statement | Feb 14, 2025 | — |
| S-1/A | Amended registration statement | Nov 27, 2024 | — |
| CORRESP | Letter to the SEC | Nov 1, 2024 | — |
| S-1/A | Amended registration statement | Nov 1, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 28, 2024 | — |
| S-1 | Registration statement | Oct 16, 2024 | — |
| CORRESP | Letter to the SEC | Oct 16, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2024 | — |
| DRS/A | Filing | Sep 16, 2024 | — |
| DRSLTR | Filing | Sep 13, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2024 | — |
| DRS/A | Filing | Aug 15, 2024 | — |
| DRSLTR | Filing | Aug 14, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 17, 2024 | — |
| DRS | Filing | Jun 20, 2024 | — |
Showing 65 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CURX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Jericho, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2025942
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.